Total: $755.8M

Company (Symbol)^#

Type Of Financing

Number Of Shares, Units Or Warrants (M)

Amount Raised (M)

Investors; Placement Agents; Details (Date)^@

Acrongenomics Inc. (OTC BB: AGNM)

Private placement of stock

1S

$4

The shares were placed at $4 each (12/22)

Alchemia Ltd. (Australia; ASX: ACL)

Private placement of stock and share purchase plan

19.6S

A$21.6
(US$16.1)

Shares were sold at A$1.10 to institutional investors in a private placement in November; another A$5M was raised through a subsequent sale of stock to shareholders at the same price (12/14)

Amarin Corp. plc (UK; AMRN)

Private placement of stock and warrants

26.1S and 9.1W

$26.4

Amarin sold 26.1M American depository shares, each representing one common share, at $1.01 apiece; each warrant is exercisable at $1.43 per share; investors included Southpoint Capital Advisors LP, Biotechnology Value Fund LP, Fort Mason Capital LP and Domain Public Equity Partners LP (12/19)

Amphion Innovations plc (AIM:AMP)

Private placement of stock

3.6S

£1
(US$1.7)

The shares were sold at 27.5 pence each (12/5)

Antisoma plc (UK; LSE:ASM)

Private placement of stock

33.6S

£6.55
(US$11.5)

The shares were placed at 19.5 pence each in an oversubscribed deal; ING was placement agent (12/5)

Avanir Pharmaceuticals Inc. (AMEX:AVN)

Private placement of stock

6S

$20

Shares in the registered direct offering were sold at $3.35 each to investors that included Federated Kaufmann; the deal was initiated through Leerink Swann & Co. (12/16)

BioCryst Pharmaceuticals Inc. (BCRX)

Private placement of stock

2.229S

$30

Shares in the registered direct offering were sold at $13.46 each; investors included Kleiner Perkins Caufield & Byers and Texas Pacific Group Ventures (12/15)

BioInvent International AB (Sweden; SSE:BINV)

Rights issue

47.16S

SEK160
(US$20.3)

26% of the shares were subscribed for without preferential rights in the oversubscribed deal (12/9)

Bioniche Life Sciences Inc. (Canada; TSE:BNC)

Sale of various securities

N/A

$18.5

The deal with Laurus Funds consisted of shares, debt, convertible debt and warrants, with about $17.5M of the total being various debt (12/9)

BioTime Inc. (OTC BB:BTIM)

Rights offer of stock and warrants

4.465S and 4.465W

$1.8

Units consisting of one share and one warrant were sold at $0.40 each; the five-year warrants are exercisable at $2 per share (12/22)

CepTor Corp. (OTC BB:CEPO)

Private placement of convertible notes

N/A

$2

Cornell Capital Partners LP purchased the three-year, 8% notes, which are convertible at the lesser of 105% of the price prior to the deal, or 95% of the lowest price for 20 days before conversion (12/15)

Ceragenix Pharmaceuticals Inc. (OTC BB:CGXP)

Private placement of convertible notes

N/A

$3.2

The two-year, 10% notes are convertible into stock at $2.05 per share; investors also got five-year warrants representing half the shares that are exercisable at $2.225 per share (12/6)

Chiron Corp. (CHIR)

Private placement of stock

6.9S

$300

Novartis AG purchased the shares at $43.50 each under a subscription agreement between the companies; Novartis has offered to acquire all of Chiron (12/8)

CollaGenex Pharmaceuticals Inc. (CGPI)

Private placement of stock

2.9S

$29

CollaGenex sold the shares at $10 each in a registered direct offering; Roth Capital Partners LLC was placement agent (12/21)

Cytogen Corp. (CYTO)

Private placement of stock and warrants

3.73S and 0.932W

$13.3

The shares were sold at $3.56 each; the five-year warrants are exercisable at $4.25 per share; Rodman & Renshaw was placement agent (12/13)

Discovery Laboratories Inc. (DSCO)

Private placement of stock

3.03S

$20

The shares were sold in a registered direct offering at $6.60 each; SG Cowen & Co. LLC was placement agent (12/14)

GTC Biotherapeutics Inc. (GTCB)

Private placement of stock and warrants

9.1S and 3.6W

$16.7

Shares were sold for $1.78 each in the registered direct offering; investors also paid $0.125 per warrant; the five-year warrants are exercisable at $2.05 per share; SG Cowen & Co. LLC was lead placement agent; Rodman & Renshaw LLC was co-agent (12/8)

Halozyme Therapeutics Inc. (AMEX:HTI)

Private placement of stock and warrants

10S

$17.5

The shares were sold in a registered direct offering at $1.75 each; SG Cowen & Co. LLC was lead placement agent; Rodman & Renshaw and Roth Capital Partners were co-placement agents (12/13)

Immtech International Inc. (AMEX:IMM)

Private placement of convertible stock and warrants

N/A and 0.0835W

$3.34

Immtech sold 133,600 Series E shares at $25 per share, with each convertible into 3.5511 shares; the 83,500 three-year warrants are exercisable at $10 per share; investors have an option to purchase 25% more of the Series E shares (12/14)

Inovio Biomedical Corp. (AMEX:INO)

Private placement of stock and warrants

6.583S and 2.3W

$15.8

Shares were sold at $2.40 each, and the five-year warrants are exercisable at $2.93 per share; a group of institutional investors was joined by Merck & Co. Inc. and Vical Inc. in the deal; Thomas Weisel Partners was placement agent (12/19)

InSite Vision Inc. (AMEX:ISV)

Private placement of debt and warrants

ND

$4

The financing was obtained through Paramount BioCapital Inc.; terms of the deal were not disclosed; another $2M was expected to be invested early in January (12/30)

Lpath Therapeutics Inc. (OTC BB:LPTN)

Private placement of stock and warrants

7.5S and 0.375W

$6

The deal was completed just prior Lpath's reverse merger with the public company Neighborhood Connections Inc.; the 58-month warrants are exercisable at $1.50 per share; Roaring Fork Capital SBIC LP led the financing (12/8)

MicroIslet Inc. (AMEX:MII)

Private placement of stock and warrants

2.285S and 1.14W

$3.4

The shares were sold at about $1.50 each; the five-year warrants are exercisable at $1.65 per share (12/27)

MacroChem Corp. (OTC BB:MCHM)

Private placement of convertible notes and warrants

N/A and 100W

$2.5

The 10% notes are convertible into 100M shares of common stock; the six-year warrants are exercisable at $0.03 per share (12/28)

Neuren Pharmaceuticals Ltd. (Australia; ASX:NEU)

Private placement of stock

12S

A$6.36
US$4.75)

The shares were sold at $0.53 each in a placement co-managed by Taylor Collision Ltd. and Patersons Securities Ltd. (12/2)

Oncolytics Biotech Inc. (Canada; TSE:ONC)

Private placement of stock and warrants

3.2S and 1.6W

C$16.5
US$14.3)

Units were sold at C$5.15 each, consisting of one share and half a warrant; each whole warrant is exercisable for three years at C$6.15 per share (12/13)

OSI Pharmaceuticals Inc. (OSIP)

Private placement of convertible notes

N/A

$100

The 2% notes mature in 2025 and are convertible into stock at an initial price of $29.43 per share, a premium of 25% (12/15)

ProMetic Life Sciences Inc. (Canada;

TSE:PLI.SV)

Private placement of convertible notes

N/A

$8.9

The notes are convertible into common stock at C$0.32 per share; the notes are repayable in cash and/or stock (12/21)

SemBioSys Genetics Inc.(Canada; TSE:SBS)

Private placement of stock and warrants

3.86S and 1.932W

C$15.6
US$13.4)

Units consisting of one share and half a warrant were placed at C$4 apiece; each whole warrant is exercisable for 30 months at C$5.50 per share; underwriters, led by Orion Securities Inc. and including Versant Partners Inc., Canaccord Capital Corp. and Westwind Partners Inc., exercised their option on an additional 1.3M units in the deal (12/6)

Stressgen Biotechnologies Corp. (Canada; TSE:SSB)

Private placement of stock and warrants

2.685S and 0.9W

C$0.94
US$0.81)

Canaccord Capital Corp. exercised its overallotment option to purchase additional units from a C$2.68M financing completed in November; the two-year warrants are exercisable at C$0.50 per share (12/14)

Vernalis plc (UK; VNLS)

Private placement of stock

24.28S

£15.3
US$26.6)

Proceeds from the placement were received by former Cita NeuroPharmaceuticals Inc. shareholders as part of Vernalis' acquisition of Cita; Piper Jaffray was placement agent (12/14)

Notes:

This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt.

^# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

Currency conversions are based on exchange rates at the time of the deal.

N/A = Not applicable; ND = Not disclosed.

AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange.